• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    Q BioMed Inks Strontium89 Supply Pact

    PCI Pharma Services Appoints SVP, CFO
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Completes OXGENE Acquisition

    Celonic Group Announces Plans for New Facility in Switzerland

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    WuXi AppTec Completes OXGENE Acquisition

    Live Webinar - Formulation Strategies for Poorly Soluble Molecules

    Celonic Group Announces Plans for New Facility in Switzerland
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    PCI Pharma Services

    Alcami

    Federal Equipment Company

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Aphena Pharma Solutions

    Syngene

    Adare Pharma Solutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Seattle Genetics and Merck Partner

    Announce two strategic oncology collaborations.

    Related CONTENT
    • BioDuro, Sundia Partner as New CRDMO
    • Lantern Pharma and Fox Chase Cancer Center Collaborate
    • Boehringer, Mirati Therapeutics Enter Clinical Collaboration
    • Thermo Fisher Scientific to Collaborate with AstraZeneca and UNMC
    • Evotec and Bioaster Partner
    Contract Pharma Staff09.14.20
    Seattle Genetics Inc. and Merck, known as MSD outside the United States and Canada, have announced two new strategic oncology collaborations.
     
    The companies will globally develop and commercialize Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting LIV-1, which is currently in phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. Under the terms of the agreement, Seattle Genetics will also receive a $600 million upfront payment and Merck will make a $1.0 billion equity investment in 5.0 million shares of Seattle Genetics common stock at a price of $200 per share. In addition, Seattle Genetics is eligible for progress-dependent milestone payments of up to $2.6 billion.
     
    Separately, Seattle Genetics has granted Merck an exclusive license to commercialize TUKYSA (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of Her2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Seattle Genetics will receive $125 million from Merck as an upfront payment and is eligible for progress-dependent milestones of up to $65 million.
     
    “These two strategic collaborations will enable us to further diversify Merck’s broad oncology portfolio and pipeline, and to continue our efforts to extend and improve the lives of as many patients with cancer as possible,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “We look forward to working with the team at Seattle Genetics to advance the clinical program for ladiratuzumab vedotin, which has shown compelling signals of efficacy in early studies, and to bring TUKYSA to even more patients with cancer around the world.”
     
    Ladiratuzumab Vedotin Collaboration
     
    Under the terms of the agreement, Seattle Genetics and Merck will collaborate and equally share costs on the global development of ladiratuzumab vedotin and other LIV-1-targeting ADCs. The companies have agreed to jointly develop and share future costs and profits for ladiratuzumab vedotin on a 50:50 basis worldwide. Merck will pay Seattle Genetics $600 million upfront and make a $1.0 billion equity investment in 5.0 million shares of Seattle Genetics common stock at a price of $200 per share. In addition, Seattle Genetics will be eligible to receive up to $2.6 billion in milestone payments, including $850 million in development milestones and $1.75 billion in sales milestones.
     
    The companies will jointly develop and commercialize ladiratuzumab vedotin and equally share profits worldwide. The companies will co-commercialize in the U.S. and Europe. Seattle Genetics will be responsible for marketing applications for approval in the U.S. and Canada, and will record sales in the U.S., Canada and Europe. Merck will be responsible for marketing applications for approval in Europe and in countries outside the U.S. and Canada, and will record sales in countries outside the U.S., Europe and Canada. Including the upfront payment, equity investment proceeds and potential milestone payments, Seattle Genetics is eligible to receive up to $4.2 billion.
     
    TUKYSA Collaboration

    Merck has been granted exclusive rights to commercialize TUKYSA in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Seattle Genetics retains commercial rights and will record sales in the U.S., Canada and Europe. Merck will be responsible for marketing applications for approval in its territory, supported by the positive results from the Her2Climb clinical trial.
     
    Merck will also co-fund a portion of the TUKYSA global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Seattle Genetics will continue to lead ongoing TUKYSA global development planning and operational execution. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territory.
     
    Seattle Genetics will receive from Merck $125 million as an upfront payment and is eligible to receive progress-dependent milestones of up to $65 million. Seattle Genetics will also receive $85 million in prepaid research and development payments to be applied to Merck’s global development funding obligations. In addition, Seattle Genetics would receive tiered royalties on sales of TUKYSA in Merck’s territory.
    Related Searches
    • Drug Development
    • Clinical Trials
    Suggested For You
    BioDuro, Sundia Partner as New CRDMO BioDuro, Sundia Partner as New CRDMO
    Lantern Pharma and Fox Chase Cancer Center Collaborate Lantern Pharma and Fox Chase Cancer Center Collaborate
    Boehringer, Mirati Therapeutics Enter Clinical Collaboration Boehringer, Mirati Therapeutics Enter Clinical Collaboration
    Thermo Fisher Scientific to Collaborate with AstraZeneca and UNMC Thermo Fisher Scientific to Collaborate with AstraZeneca and UNMC
    Evotec and Bioaster Partner Evotec and Bioaster Partner
    Cobra Biologics and CombiGene Partner Cobra Biologics and CombiGene Partner
    Florence, Pfizer Partner to Support COVID-19 Vax Florence, Pfizer Partner to Support COVID-19 Vax
    AnGes, Brickell Biotech Partner on DNA Vax for COVID-19 AnGes, Brickell Biotech Partner on DNA Vax for COVID-19
    Stevanato Group, Nelson Labs Sign E&L Testing Pact Stevanato Group, Nelson Labs Sign E&L Testing Pact
    Avomeen, Daré Partner to Accelerate Daré’s Pipeline Avomeen, Daré Partner to Accelerate Daré’s Pipeline
    NanoImaging, Thermo Fisher Partner for cryoEM Tech NanoImaging, Thermo Fisher Partner for cryoEM Tech
    Bilim Pharmaceuticals, H&T Presspart and Hovione Collaborate Bilim Pharmaceuticals, H&T Presspart and Hovione Collaborate
    Idorsia Partners with Syneos Health Idorsia Partners with Syneos Health
    Humanetics Partners with Pharmaceutics International Humanetics Partners with Pharmaceutics International
    Roche, Regeneron Partner to Increase Global Supply of REGN-COV2 Roche, Regeneron Partner to Increase Global Supply of REGN-COV2

    Related Breaking News

    • Breaking News | Clinical Trials
      Strata Oncology Unveils Strata PATH Trial

      Strata Oncology Unveils Strata PATH Trial

      The new platform clinical trial will evaluate FDA-approved therapies in novel biomarker profiles learned from real-world data.
      Charles Sternberg, Assistant Editor 03.02.21

    • Breaking News | Clinical Trials | CRO News | Information Technology
      Alimentiv Acquires McDougall Scientific

      Alimentiv Acquires McDougall Scientific

      Niche CRO specializes in statistical analysis, data management, reporting, and clinical trial design.
      Kristin Brooks 03.02.21

    • Breaking News | Clinical Trials | Collaborations & Alliances | Industry News | Information Technology
      Ashfield Engage, Popit Form Digital Monitoring Collaboration

      Ashfield Engage, Popit Form Digital Monitoring Collaboration

      Partner to improve patient adherence through supplemental real-time personalized support.
      Tim Wright, Editor, Contract Pharma 02.26.21


    • Breaking News | Collaborations & Alliances | Drug Development | Industry News | Solid Dosage/Creams/Ointments
      Pfizer Partners with Medicines Manufacturing Innovation Center

      Pfizer Partners with Medicines Manufacturing Innovation Center

      To transform the formulation of oral solid dosage medicines.
      Tim Wright, Editor, Contract Pharma 02.25.21

    • Breaking News | Drug Development | Industry News
      Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

      Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

      Sentynl acquires CUTX-101 Copper Histidinate for the treatment of Menkes disease for $20 million in upfront and regulatory milestones.
      Kristin Brooks 02.24.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News | Information Technology
      Pfizer Selects Seven Bridges to Support RNA Sequencing Data

      Pfizer Selects Seven Bridges to Support RNA Sequencing Data

      Seven Bridges will centralize and manage terabytes scRNASeq data, which provides detailed analysis of gene expression in individual cells.
      Kristin Brooks 02.24.21


    • Breaking News | Drug Development | Promotions & Moves
      Aevitas Therapeutics Appoints President and CEO

      Aevitas Therapeutics Appoints President and CEO

      Dr. Markus Peters offers a 25-year track record of developing and commercializing orphan and specialty pharmaceuticals.
      Charles Sternberg, Assistant Editor 02.22.21

    • Bio News | Breaking News | cGMP Manufacture | Clinical Trial Materials | Clinical Trials | Collaborations & Alliances | Industry News
      RedHill and Cosmo Strengthen Manufacturing Agreements

      RedHill and Cosmo Strengthen Manufacturing Agreements

      Secures manufacturing capacity of Movantik for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.
      Tim Wright, Editor, Contract Pharma 02.19.21

    • Breaking News | Collaborations & Alliances | Drug Development
      Lilly, Rigel Enter Exclusive CNS Development Collaboration

      Lilly, Rigel Enter Exclusive CNS Development Collaboration

      Lilly will pay $125 million upfront and up to $835 million in potential milestones for Rigel's lead RIPK1 inhibitor, R552.
      Kristin Brooks 02.18.21


    • Breaking News | Clinical Trials | CRO News
      PPD Awarded US Army RPA Develop PTSD Drugs

      PPD Awarded US Army RPA Develop PTSD Drugs

      Adaptive platform clinical research trial design aims to expedite potential new treatments for veterans.
      Kristin Brooks 02.18.21

    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
      Biomunex, Onward Ink Strategic Antibody Development Pact

      Biomunex, Onward Ink Strategic Antibody Development Pact

      Exclusive worldwide license and development agreement will leverage Biomunex' next gen bi- and multi-specific antibody platform in hematological malignancies.
      Kristin Brooks 02.16.21

    • APIs | Breaking News | Drug Development | Formulation Development | Industry News | Solid Dosage/Creams/Ointments
      Lonza Expands Solid Small Molecule Services

      Lonza Expands Solid Small Molecule Services

      To encompass all aspects of solid form screening and characterization of small molecule APIs.
      Kristin Brooks 02.16.21


    • Bio News | Breaking News | Clinical Trial Materials | Clinical Trials | Collaborations & Alliances | Industry News
      Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

      Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

      For EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody.
      Tim Wright, Editor, Contract Pharma 02.12.21

    • Biologics, Proteins, Vaccines | Collaborations & Alliances | Drug Development
      Molecular Templates, BMS Enter Strategic Research Pact

      Molecular Templates, BMS Enter Strategic Research Pact

      Aims to discover and develop multiple therapies for specific oncology targets utilizing MTEM’s next-gen engineered toxin body (ETB) platform.
      Kristin Brooks 02.11.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      AbbVie, Caribou Ink CAR-T Collaboration

      AbbVie, Caribou Ink CAR-T Collaboration

      Leverages Caribou's next-generation CRISPR genome editing technology platform and AbbVie's antigen-specific binders.
      Tim Wright, Editor, Contract Pharma 02.10.21

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    Breaking News
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    • Alimentiv Acquires McDougall Scientific
    • Q BioMed Inks Strontium89 Supply Pact
    • PCI Pharma Services Appoints SVP, CFO
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    AHPA Submits Comments to FDA on Proposed Traceability Rule
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    AOC Announces EMEA Price Increase
    Mule-Hide Products Co. Introduces Seal-Fast Liqui-Flash
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    NAMSA Acquires American Preclinical Services
    Quidel's QuickVue At-Home COVID-19 Test Earns EUA
    Memic Receives FDA Marketing Authorization for Hominis
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial
    Alimentiv Acquires McDougall Scientific
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    IT Cosmetics Supports Women’s Confidence
    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Happi

    Latest Breaking News From Happi

    Croda International Acquires Alban Muller
    Givaudan Active Beauty Launches Omegablue
    Sozio Acquires Scentessence
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Abbott Label installs Domino K600i dual bar digital UV inkjet printer
    Crossmark turns to Eagle Systems for cold foil
    Maxcess launches Tidland PressureMax Airshaft Pressure Monitoring System
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Domtar Completes Sale of Personal Care Business
    Mitsui to Sell Chinese Nonwovens Business
    Dr. J's Disinfectant Wipes Approved for Distribution in CA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    SeaSpine Releases Reef TO (TLIF Oblique) Interbody System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login